<DOC>
	<DOCNO>NCT00383292</DOCNO>
	<brief_summary>The primary purpose study determine objective response rate ( complete partial response ) patient receive LY573636 one prior systemic treatment unresectable metastatic melanoma .</brief_summary>
	<brief_title>A Study LY573636 Treating Patients With Malignant Melanoma</brief_title>
	<detailed_description>Patients receive 2-hour intravenous infusion study drug ( LY573636 ) every 28 day . Radiological imaging scan perform first dose study drug every treatment . Patients assess clinical progression every visit response approximately every 56 day ( every cycle ) .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Diagnosis malignant melanoma unresectable metastatic ( Stage III IV ) Have receive 1 previous systemic treatment regimen unresectable metastatic melanoma . An immunotherapy antibodybased regimen ( include vaccinationbased treatment ) count prior treatment regimen determine study eligibility , unless combine chemotherapeutic target anticancer drug . Have discontinue previous therapy cancer , include chemotherapy , radiotherapy , immunotherapy , investigational therapy least 30 day Serious preexist medical condition Have receive two previous treatment regimen unresectable metastatic melanoma Have second primary cancer ( unless diseasefree 2 year ) Active treatment Warfarin ( Coumadin ) Primary ocular mucosal melanoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>